Oloa

S-(+)-Methyl-(2-chlorophenyl)[(2-(2-thienyl)amino] acetate hydrochloride, e taʻua foʻi o S-(+)-Clopidogrel, o se vailaʻau vailaʻau faʻatasi ai ma se vailaʻau vailaʻau o C16H16ClNO2S·HCl O se chiral derivative o clopidogrel, lea o se vailaau antiplatelet taua.O le faaaogaina muamua o le S-(+)-Methyl-(2-chlorophenyl)[(2-(2-thienyl)amino] acetate hydrochloride e pei o se malosi vaega i le fausiaina o vailaʻau cardiovascular, aemaise lava antiplatelet agents. E faʻaaogaina ona aʻafiaga e ala i le taofiofia o le faʻapipiʻiina o platelet, puipuia le faʻatupuina o le toto, ma faʻaitiitia ai le lamatiaga o faʻalavelave cardiovascular. O le sao taua i le faʻagaoioia ma le faʻapipiʻiina o platelets. E ala i le fusia e le mafai ona faʻaaogaina i lenei tali, S-(+)-Methyl-(2-chlorophenyl)[(2-(2-thienyl)amino] acetate hydrochloride e taofia ai le faʻagaioiina o platelet ma taofia ai le fausiaina. o le fa'atupu toto. O lenei faiga e fai ma vaila'au taua mo le puipuia o mea e tutupu i le thrombotic i tagata mama'i e maualuga le lamatiaga, e pei o i latou o lo'o i ai se tala'aga o le ma'i tigaina o le fatu, ischemic stroke, po'o le ma'i o le alatoto.S-(+)-Methyl- (2-chlorophenyl) [(2-(2-thienyl)amino] acetate hydrochloride e masani ona tuʻuina tautala i foliga o papa poʻo capsules.A maeʻa le faʻaogaina, e maua ai se suiga i le ate e gaosia ai lona metabolite malosi.O lenei metabolite malosi o loʻo fusifusia e le mafai ona faʻafeiloaʻi i le P2Y12 receptor, faʻaaogaina ona aʻafiaga antiplatelet mo se taimi umi.O le faʻapipiʻi e masani ona faʻatonuina tasi i aso uma, a le o se togafitiga faʻapitoa poʻo le tuʻufaʻatasia ma isi vailaʻau antiplatelet, e pei ole aspirin. E taua le maitauina o le S-(+)-Methyl-(2-chlorophenyl)[(2-(2). -thienyl)amino] acetate hydrochloride e tatau ona faʻaaogaina i lalo o le taʻitaʻiga a se fomaʻi soifua maloloina, ona o lona faʻaaogaina e ono mafai